Data points sourced directly from the paper's production metrics (73,000 hens; 63,000 kg powder) and pilot group (7 hens)
Paper states each 800 mg tablet contains 120 mg egg-yolk powder with β5.4 mg IgY per tablet (authors' estimate based on egg-yolk IgY content)
Scoring is relative and derived from the paper's data: strong laboratory and manufacturing evidence, but minimal clinical human data (hence low score for human PK/efficacy). All values and categories are taken from the article's reported experiments and limitations
All suggested experiments address the paper's key weaknesses (translation to human protection, safety, robustness to viral evolution, and manufacturing reproducibility) and would materially change clinical or policy conclusions if results are negative or positive.
Full paper used as primary source:
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.